Cytosurge and Bruker partnership enables FluidFM single cell experiments on BioScope Resolve BioAFM

Cytosurge AG, a Swiss company that develops, manufactures and distributes scientific high-precision nanotechnology instruments and robotic systems based on its patented FluidFM® technology, and Bruker Corporation, one of the world's leading analytical instrumentation companies, have entered into a new partnership.

Thanks to this Premium partnership, researchers can combine the femtoliters scale fluid control and cell treatment precision of FluidFM with the force control, resolution and speed available with Bruker’s exclusive PeakForce Tapping® technology.

Due to the new combination with Cytosurge’s FluidFM technology, the BioScope Resolve® BioAFM now becomes an even more powerful tool. The exclusive PeakForce QNM® and FastForce Volume™ capabilities of the BioScope Resolve combined with FluidFM technology opens a broad range of FluidFM applications for BioScope Resolve BioAFM users – from single cell adhesion and injection into single cells, through colloidal studies to nanolithography.

Dr. Pascal Behr, CEO of Cytosurge AG, is very pleased about the new Premium partnership:

Working together with Bruker as one of the world’s leading AFM providers marks an important milestone for Cytosurge. This new Premium partnership reinforces our vision of enabling the full potential of FluidFM technology for the benefit of researchers world-wide. We expect to see many exciting innovations and new applications when our technology is coupled with those of our partners. This new Premium collaboration with Bruker will enable us to deliver highly integrated and versatile FluidFM solutions based on Bruker’s state-of-the-art AFM product portfolio - starting today with the Bruker BioScope Resolve AFM."

Also David V. Rossi, Executive Vice President and General Manager of Bruker's AFM Business, is satisfied:

Partnering with Cytosurge to integrate FluidFM with BioScope Resolve and PeakForce Tapping technology fits perfectly with our strategy to take BioAFM experiments beyond imaging, from mechanobiology and drug delivery to the probing of biochemical interactions. Manipulating cells, and injecting biomolecules into cells while sensing piconewton forces, and imaging at the nanometer scale, are AFM capabilities that enable fundamentally new correlative information."

The Partnership with Bruker is the third of a series between Cytosurge and leading AFM manufacturers, designed to make FluidFM available to as many AFM users as possible. Dr. Michael Gabi, CTO of Cytosurge, describes the FluidFM AFM Partnership Program:

We work closely together with established AFM manufacturers to deliver high quality solutions and maximize customer value. Our unique program will allow new and existing AFM owners to leverage their AFM investments to their full potential."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post